GLIPVAS 50 TAB is a potent oral antidiabetic formulation comprising Vildagliptin 50 mg, a member of the DPP-4 (Dipeptidyl Peptidase-4) inhibitor class, used extensively in the treatment of Type 2 Diabetes Mellitus (T2DM). It helps regulate blood sugar levels by enhancing the body’s natural incretin system, thereby improving insulin secretion and reducing glucagon levels after meals.
This formulation is produced by BluepillExpress, a globally reputed third-party pharmaceutical manufacturing company, compliant with WHO-GMP and ISO quality systems. Known for its consistency and robust export capabilities, BluepillExpress supplies GLIPVAS 50 TAB to distributors, hospitals, pharmacies, and tender markets across Asia, Africa, the Middle East, LATAM, and more.
Mechanism of Action
Vildagliptin inhibits the DPP-4 enzyme, which is responsible for the rapid degradation of incretin hormones such as GLP-1 and GIP. By increasing the concentration of these hormones, it enhances glucose-dependent insulin secretion from pancreatic beta cells and suppresses glucagon release from alpha cells. This results in a reduction of both fasting and postprandial blood glucose levels.
Indications
Type 2 Diabetes Mellitus (as monotherapy or combination therapy)
For patients inadequately controlled with diet and exercise alone
Suitable as an add-on to Metformin, Sulfonylureas, or Thiazolidinediones
Dosage and Administration
Recommended Dose: 50 mg once or twice daily depending on glycemic control needs
Maximum Dose: 100 mg/day
Administered orally, with or without food
Dosage adjustment required in renal impairment
Not recommended in patients with Type 1 Diabetes or Diabetic Ketoacidosis
Pharmacokinetics
Absorption: Rapid, with peak plasma concentration within 1.5 hours
Bioavailability: Approximately 85%
Elimination: Primarily via kidneys (unchanged and metabolites)
Half-life: 2-3 hours
Description provided by bluepill express.
FIEO Registered
Export Ready
